Entegris (ENTG) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales were $813 million, down 10% year-over-year but up 5% sequentially; adjusted net sales (excluding divestitures) rose 6% year-over-year and 10% sequentially, with all divisions posting sequential growth.

• Gross margin improved to 46.2% in Q2 2024 from 42.6% a year ago, driven by better plant utilization and divestitures.

• Adjusted EBITDA margin was 27.8% of revenue, with non-GAAP EPS at $0.71.

• Net income for Q2 2024 was $67.7 million (GAAP), with diluted EPS of $0.45.

• Strategic investments in new facilities and R&D are ongoing, with initial revenue from Taiwan and up to $75 million in CHIPS Act funding for Colorado.

Financial highlights

• Q2 2024 net sales: $813 million (down 10% year-over-year, up 5% sequentially); adjusted net sales up 6% year-over-year and 10% sequentially.

• Gross margin: 46.2% (GAAP and non-GAAP); adjusted EBITDA: $226 million (27.8% margin).

• GAAP net income: $67.7 million; non-GAAP net income: $107.1 million; GAAP EPS: $0.45; non-GAAP EPS: $0.71.

• Free cash flow: $52 million; CapEx: $59 million in Q2; cash and cash equivalents at quarter-end: $320 million.

• Ending gross debt: ~$4.12 billion; net debt: ~$3.9 billion.

Outlook and guidance

• 2024 sales expected at approximately $3.3 billion, reflecting slower market recovery and FX headwinds; full-year guidance is for 7% top-line growth versus 2023, and 11% growth in H2 versus H1, excluding divestitures.

• Q3 2024 sales guidance: $820–$840 million; adjusted EBITDA margin: 28.5%–29.5%; non-GAAP EPS: $0.75–$0.80.

• 2024 EBITDA expected at ~29% of revenue; non-GAAP EPS at ~$3.15.

• Gross margin for Q3 expected at 46%–47%.

• Management expects gradual semiconductor market recovery in H2 2024 and strong growth acceleration into 2025.